Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 2.38
NAS:CLVS's Cash-to-Debt is ranked lower than
76% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:CLVS: 2.38 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CLVS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.91  Med: N/A Max: No Debt
Current: 2.38
Equity-to-Asset 0.41
NAS:CLVS's Equity-to-Asset is ranked lower than
84% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:CLVS: 0.41 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CLVS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.41 Max: 0.75
Current: 0.41
0.33
0.75
Piotroski F-Score: 2
Altman Z-Score: 1.25
Beneish M-Score: -3.08
WACC vs ROIC
11.90%
-2667.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1131.02
NAS:CLVS's Operating Margin % is ranked lower than
90% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:CLVS: -1131.02 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CLVS' s Operating Margin % Range Over the Past 10 Years
Min: -477862.82  Med: -239512.91 Max: -1131.02
Current: -1131.02
-477862.82
-1131.02
Net Margin % -1709.08
NAS:CLVS's Net Margin % is ranked lower than
90% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:CLVS: -1709.08 )
Ranked among companies with meaningful Net Margin % only.
NAS:CLVS' s Net Margin % Range Over the Past 10 Years
Min: -447611.54  Med: -224393.04 Max: -1174.54
Current: -1709.08
-447611.54
-1174.54
ROE % -270.57
NAS:CLVS's ROE % is ranked lower than
93% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:CLVS: -270.57 )
Ranked among companies with meaningful ROE % only.
NAS:CLVS' s ROE % Range Over the Past 10 Years
Min: -270.57  Med: -83.7 Max: -26.78
Current: -270.57
-270.57
-26.78
ROA % -70.73
NAS:CLVS's ROA % is ranked lower than
75% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:CLVS: -70.73 )
Ranked among companies with meaningful ROA % only.
NAS:CLVS' s ROA % Range Over the Past 10 Years
Min: -144.39  Med: -51.12 Max: -21.25
Current: -70.73
-144.39
-21.25
ROC (Joel Greenblatt) % -8020.86
NAS:CLVS's ROC (Joel Greenblatt) % is ranked lower than
84% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:CLVS: -8020.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CLVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9748.56  Med: -7941.19 Max: -3834.63
Current: -8020.86
-9748.56
-3834.63
3-Year EBITDA Growth Rate 48.70
NAS:CLVS's 3-Year EBITDA Growth Rate is ranked higher than
88% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:CLVS: 48.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:CLVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -53.4  Med: 8.65 Max: 51.8
Current: 48.7
-53.4
51.8
3-Year EPS without NRI Growth Rate 45.40
NAS:CLVS's 3-Year EPS without NRI Growth Rate is ranked higher than
89% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:CLVS: 45.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:CLVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -53.1  Med: 7.15 Max: 48.8
Current: 45.4
-53.1
48.8
GuruFocus has detected 3 Warning Signs with Clovis Oncology Inc $NAS:CLVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CLVS's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

CLVS Guru Trades in Q3 2016

Louis Moore Bacon 95,000 sh (New)
Columbia Wanger 204,000 sh (New)
Jim Simons Sold Out
» More
Q4 2016

CLVS Guru Trades in Q4 2016

John Burbank 381,814 sh (New)
Chuck Royce 76,000 sh (New)
Jim Simons 82,100 sh (New)
Columbia Wanger 189,958 sh (-6.88%)
» More
Q1 2017

CLVS Guru Trades in Q1 2017

Jim Simons 153,400 sh (+86.85%)
Chuck Royce 76,000 sh (unchged)
Columbia Wanger Sold Out
John Burbank 202,804 sh (-46.88%)
Louis Moore Bacon 40,000 sh (-57.89%)
» More
Q2 2017

CLVS Guru Trades in Q2 2017

Joel Greenblatt 3,727 sh (New)
Steven Cohen 30,000 sh (New)
Ron Baron 15,015 sh (New)
Leon Cooperman 50,000 sh (New)
Jim Simons 326,200 sh (+112.65%)
John Burbank Sold Out
Chuck Royce 66,000 sh (-13.16%)
Louis Moore Bacon 10,000 sh (-75.00%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:CLVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Leon Cooperman 2017-06-30 New Buy0.2%$45.93 - $96.78 $ 71.2017%50,000
Ron Baron 2017-06-30 New Buy0.01%$45.93 - $96.78 $ 71.2017%15,015
Joel Greenblatt 2017-06-30 New Buy$45.93 - $96.78 $ 71.2017%3,727
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ACAD, NAS:PTLA, NAS:SAGE, NAS:PBYI, NAS:AVXS, NAS:FGEN, NAS:JUNO, NAS:NKTR, NAS:BLUE, NAS:ONCE, NAS:AGIO, NAS:LGND, NAS:TECH, NAS:ICPT, NAS:NBIX, NAS:RARE, NAS:SRPT, NAS:LOXO, NYSE:XON, NAS:FOLD » details
Traded in other countries:C6O.Germany,
Headquarter Location:USA
Clovis Oncology Inc is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.

Clovis Oncology Inc is operative in the healthcare sector based in the United States. As a pharmaceutical manufacturer, it is focused on developing and commercializing anti-cancer agents. Its suite of product candidates includes Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor for the treatment of non-small cell lung cancer. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. The company's revenue primarily depends on the sale of Rucaparib in the United States market.

Ratios

vs
industry
vs
history
PB Ratio 10.08
CLVS's PB Ratio is ranked lower than
94% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CLVS: 10.08 )
Ranked among companies with meaningful PB Ratio only.
CLVS' s PB Ratio Range Over the Past 10 Years
Min: 1.28  Med: 4.72 Max: 18.33
Current: 10.08
1.28
18.33
PS Ratio 147.12
CLVS's PS Ratio is ranked lower than
95% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. CLVS: 147.12 )
Ranked among companies with meaningful PS Ratio only.
CLVS' s PS Ratio Range Over the Past 10 Years
Min: 31.02  Med: 136.1 Max: 445.75
Current: 147.12
31.02
445.75
EV-to-EBIT -8.54
CLVS's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. CLVS: -8.54 )
Ranked among companies with meaningful EV-to-EBIT only.
CLVS' s EV-to-EBIT Range Over the Past 10 Years
Min: -26  Med: -9.9 Max: -1.4
Current: -8.54
-26
-1.4
EV-to-EBITDA -8.59
CLVS's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. CLVS: -8.59 )
Ranked among companies with meaningful EV-to-EBITDA only.
CLVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -27  Med: -10.2 Max: -1.5
Current: -8.59
-27
-1.5
Current Ratio 3.26
CLVS's Current Ratio is ranked higher than
71% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CLVS: 3.26 )
Ranked among companies with meaningful Current Ratio only.
CLVS' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 8.1 Max: 31.09
Current: 3.26
0.86
31.09
Quick Ratio 3.23
CLVS's Quick Ratio is ranked higher than
71% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. CLVS: 3.23 )
Ranked among companies with meaningful Quick Ratio only.
CLVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 8.1 Max: 31.09
Current: 3.23
0.86
31.09
Days Inventory 204.37
CLVS's Days Inventory is ranked lower than
86% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. CLVS: 204.37 )
Ranked among companies with meaningful Days Inventory only.
CLVS' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 204.37
Current: 204.37
0
204.37
Days Sales Outstanding 19.26
CLVS's Days Sales Outstanding is ranked lower than
79% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. CLVS: 19.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
CLVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 19.26  Med: 313.54 Max: 566.22
Current: 19.26
19.26
566.22
Days Payable 1.00
CLVS's Days Payable is ranked lower than
89% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. CLVS: 1.00 )
Ranked among companies with meaningful Days Payable only.
CLVS' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 56898.29 Max: 56898.29
Current: 1
1
56898.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.50
CLVS's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. CLVS: -4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CLVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -194.7  Med: -14.2 Max: -4.5
Current: -4.5
-194.7
-4.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 20.94
CLVS's Price-to-Net-Cash is ranked lower than
96% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. CLVS: 20.94 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CLVS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.45  Med: 11.91 Max: 61.22
Current: 20.94
2.45
61.22
Price-to-Net-Current-Asset-Value 16.52
CLVS's Price-to-Net-Current-Asset-Value is ranked lower than
96% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. CLVS: 16.52 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CLVS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.43  Med: 11.5 Max: 43.02
Current: 16.52
2.43
43.02
Price-to-Tangible-Book 13.26
CLVS's Price-to-Tangible-Book is ranked lower than
97% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CLVS: 13.26 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CLVS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.39  Med: 10.54 Max: 396.95
Current: 13.26
2.39
396.95
Price-to-Median-PS-Value 1.08
CLVS's Price-to-Median-PS-Value is ranked lower than
93% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CLVS: 1.08 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CLVS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.75  Med: 1.14 Max: 2.92
Current: 1.08
0.75
2.92
Earnings Yield (Greenblatt) % -11.68
CLVS's Earnings Yield (Greenblatt) % is ranked higher than
51% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. CLVS: -11.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CLVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -70.4  Med: -10.1 Max: -3.9
Current: -11.68
-70.4
-3.9

More Statistics

Revenue (TTM) (Mil) $21.67
EPS (TTM) $ -8.74
Beta1.74
Short Percentage of Float19.13%
52-Week Range $16.61 - 99.45
Shares Outstanding (Mil)48.88

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 72 264 525
EPS ($) -7.62 -2.64 1.91
EPS without NRI ($) -7.62 -2.64 1.91
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:CLVS

Headlines

Articles On GuruFocus.com
Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board Jun 14 2017 
Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test Apr 27 2017 
Kyle Bass Purchases Stake in Clovis Oncology May 25 2016 
Kyle Bass Builds Bull Case for Clovis Oncology Nov 27 2015 
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
VBI Vaccines (VBIV) and Clovis Oncology (CLVS) Momentum Indicators; Wynn Resorts (WYNN) Power Battle Apr 07 2015 

More From Other Websites
Tesaro: Losing Its Edge? Aug 18 2017
Ovarian Cancer Market Still Up For Grabs Aug 18 2017
Analysts’ Recommendations for Bristol-Myers Squibb in August 2017 Aug 18 2017
Clovis Oncology, Inc. – Value Analysis (NASDAQ:CLVS) : August 17, 2017 Aug 16 2017
See what the IHS Markit Score report has to say about Clovis Oncology Inc. Aug 16 2017
Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses Aug 15 2017
Edited Transcript of CLVS earnings conference call or presentation 2-Aug-17 8:30pm GMT Aug 13 2017
IHS Markit Score Update: Drop in demand for ETFs holding Clovis Oncology Inc is a negative sign for... Aug 10 2017
Biotech: Why Clovis And Tesaro Look Well Positioned Aug 09 2017
A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision Aug 08 2017
Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : August 4,... Aug 04 2017
One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce? Aug 03 2017
Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses Aug 03 2017
Clovis reports 2Q loss Aug 02 2017
Clovis Oncology Announces Second Quarter 2017 Operating Results Aug 02 2017
Investor Network: Clovis Oncology, Inc. to Host Earnings Call Aug 02 2017
Why Clovis Oncology Tumbled 13.5% Today Jul 31 2017
Why Clovis Oncology, Gulfport Energy, and Hertz Global Holdings Slumped Today Jul 31 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}